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have been durable. Unfortunately, the synthetic materials
are not viable, they do not grow, and they do not provide
pulsatile flow. Children with heart defects who receive
these materials for repair of cardiac lesions often outgrow
the patches. Stenosis or obstruction caused by the materi-
als occasionally necessitates reoperation for replacement
of the patch. Furthermore, the synthetic patches are a “for-
eign body” and may be thrombogenic and infected.
Nonsynthetic patches such as autologous pericardium
have also been used to repair cardiac defects. These patch-
es may be more resistant to infection1 and may have
growth potential.2 The autologous pericardium, however,
is fibrous tissue that has limited elasticity and may shrink,
calcify, or dilate and form an aneurysm. 
Using cell culture technology, we constructed a cell-
seeded biodegradable cardiac graft.3,4 We seeded cul-
Synthetic materials have long been used in neonates andchildren for repair of congenital cardiac defects.
Patches made of materials such as expanded polytetraflu-
oroethylene or glutaraldehyde-treated xenopericardium
Objective: The synthetic materials currently available for the repair of car-
diac defects are nonviable, do not grow as the child develops, and do not con-
tract synchronously with the heart. We developed a beating patch by seeding
fetal cardiomyocytes in a biodegradable scaffold in vitro. The seeded patch-
es survived in the right ventricular outflow tract of adult rats.
Methods: Cultured fetal or adult rat heart cells (1 × 106 cells) were seeded
into a gelatin sponge (15 × 15 × 1 mm), and the cell number was expanded
in culture for 1 or 3 weeks, respectively. The free wall of the right ventricu-
lar outflow tract in syngeneic adult rats was resected and repaired with either
unseeded patches or patches seeded with either fetal or adult cardiomyocytes
(n = 10 for each group). The patches were examined histologically over a 12-
week period. 
Results: A significant inflammatory reaction was noted in the patch at 4
weeks as the scaffold dissolved. At 12 weeks, the gelatin scaffold had com-
pletely dissolved. Both types of the seeded cells were detected in the patch
with 5-bromo-2´-deoxyuridine staining, and they maintained their continu-
ity. Unseeded patches had an ingrowth of fibrous tissue. The patches became
thinner between the fourth and the twelfth weeks in unseeded (P = .003),
fetal (P = .0001), and adult (P = .07) cardiomyocyte groups as the scaffold
dissolved. The control patch, but not the cell-seeded patches, was thinner
than the normal right ventricular outflow tract. The endocardial surface area
of each patch was covered with endothelial cells identified by factor VIII
staining. 
Conclusions: A gelatin patch was used to replace the right ventricular outflow
tract in syngeneic rats. The seeded cells survived in the right ventricular out-
flow tract after the scaffold dissolved 12 weeks after implantation. In addition,
the unseeded patches encouraged the ingrowth of fibrous tissue as the scaffold
dissolved and the patches remained completely endothelialized.  (J Thorac
Cardiovasc Surg 2001;121:932-42) 
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tured rat fetal cardiomyocytes into the gelatin sponge
and created 3-dimensional cardiac tissue in a biode-
gradable graft. Spontaneous contraction occurred when
fetal cardiomyocytes were used.3,4 The beating patch
persisted when transplanted into a rat leg or heart, even
after the gelatin scaffold dissolved. The beating patch
may have the potential to avoid the drawbacks of syn-
thetic materials and autologous pericardium.
The purpose of this study was to assess the feasibili-
ty of transplanting a biodegradable cell-seeded patch
into the pulmonary circulation. We partially resected
the right ventricular outflow tract (RVOT) of syngene-
ic adult rats and repaired the defect either with a cell-
seeded patch or with an unseeded control patch. The
patches were examined histologically over the 12-week
period. 
Materials and methods 
Experimental animals. The Animal Care Committee of
The Toronto General Hospital approved all experimental pro-
cedures, performed according to the “Guide to the Care and
Use of Experimental Animals” of the Canadian Council on
Animal Care and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and pub-
lished by the National Academy Press, revised 1996. The
hearts of 21-day fetuses were harvested from dated pregnant
syngeneic Lewis rats (Charles River Canada Inc, Quebec,
Quebec, Canada) for fetal cardiomyocyte culture. The hearts
of the mother rats were also harvested for adult heart cell cul-
ture. Adult syngeneic Lewis rats weighing 250 to 300 g
underwent the RVOT replacement procedure. 
Cell culture and preparation for seeding. Fetal car-
diomyocytes and adult heart cells from rat hearts were iso-
lated and cultured by the method we have previously report-
ed.5 In brief, the hearts were washed in phosphate-buffered
saline (PBS) solution (millimoles per liter: NaCl, 136.9; KCl,
2.7; Na2HPO4, 8.1; and KH2PO4, 1.5; pH 7.3). After removal
of the atria and the great vessels, the ventricles were minced
with fine scissors and incubated in PBS solution containing
trypsin (0.25%), collagenase (0.1%), and glucose (0.02%) at
37°C. After 15 minutes’ digestion in trypsin and collagenase,
the cell suspension was transferred into a tube containing 30
mL of culture medium (Iscove’s modified Dulbecco’s medi-
um; Gibco Laboratory, Life Technologies, Grand Island, NY)
with 10% fetal bovine serum, 0.1 mmol/L of β-mercap-
toethanol, 100 U/mL of penicillin, and 100 µg/mL of strep-
tomycin. The digestion process was repeated 2 times. The
Fig 1. Adult heart cell-seeded patch in vitro. Hematoxylin and eosin staining of vertical sections after culturing for
3 weeks (A, 100×; B, 400×). The upper and lower surfaces were seeded sequentially. Full-thickness penetration of
the cultured cells was found.
Fig 2. Cell growth in the gelatin patch. A, Fetal cardiomyo-
cyte (FCM). B, Adult cardiomyocyte (ACM). Each point rep-
resents the mean ± the standard deviation.
Fig 3. Gross appearance of control patch at 4 weeks. A, The
anterior view. B, Vertically sliced view. C, The endocardial
surface view of the heart from a control rat. Note full thick-
ness replacement of RVOT with the patch (arrows).
A
B
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cell suspension was centrifuged at 600g for 5 minutes and the
cell pellet was resuspended in culture medium. The isolated
cells were cultured at 37°C in 5% carbon dioxide and 95% air. 
Fetal cardiomyocytes were cultured for 2 days, and the cells
were detached from the culture dishes with 1 mL of 0.05%
trypsin in PBS solution with glucose (0.02%). After addition of
2 mL of culture medium, the cell suspension was centrifuged at
600g for 5 minutes. The cell pellet was washed, resuspended in
culture medium, and centrifuged again. The cell pellet was then
resuspended in a minimum amount of culture medium (approx-
imately 50-75 µL) for seeding onto a gelatin sponge patch. The
adult heart cells were cultured for 2 weeks. The cells were then
treated with trypsin, washed, and resuspended in 50 to 75 µL
for seeding onto a gelatin sponge. 
Cell seeding onto a gelatin sponge and culture. A sheet
of gelatin sponge (Gelfoam: Pharmacia & Upjohn Co,
Kalamazoo, Mich) was cut into thin rectangular pieces (15 ×
15 × 1 mm) and immersed in culture medium. After the
excessive culture medium had been removed from the gelatin
sponge by gentle compression, each patch was placed into a
10-cm culture dish. The previously prepared cell pellets were
transferred onto the center of each patch (1 × 106 cells/patch)
and the patches were incubated. Twenty minutes after incu-
bation, a drop of culture medium was added at each corner of
the patch. After another 60 minutes of incubation, 20 mL of
culture medium was added to the culture dishes. On the sec-
ond day after the initial seeding, the patches were turned
upside-down in the culture dishes and cell seeding was
repeated in the same manner as the initial seeding. After the
second seeding, the patches with fetal cardiomyocytes were
incubated for 1 week and the adult heart cells were incubated
for 3 weeks. Culture medium was changed every 2 days.
Histology of the cell-seeded patch. At the end of the culture
period, a sample from fetal or adult cell-seeded patches was
fixed by simple immersion in 10% phosphate-buffered forma-
lin solution for 2 days. The fixed patches were cut vertically
through the center, and the slices were fixed in 5% glacial
acetic acid and methanol, embedded in paraffin, and sectioned
to produce 10-µm–thick specimens. The sections were stained
with hematoxylin and eosin, as described in the manufacturer’s
specifications (Sigma Diagnostics, St Louis, Mo). 
Cell number and growth curve of the cell-seeded patch.
The cells within the patches were counted to generate a
growth curve for a period of 1 to 3 weeks (n = 2 for each peri-
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od). The patch was incubated in 7 mL of PBS solution con-
taining collagenase (0.07%) and glucose (0.02%) at 37°C
with agitation until completely dissolved (10-40 minutes).
The cell suspension was centrifuged at 600g for 5 minutes,
and the cell pellet was resuspended in 1 mL of 0.05% trypsin
in PBS solution with glucose (0.02%) at 37°C for 1 minute.
Then 9 mL of culture medium was added to terminate diges-
tion. From this cell suspension, 0.25 mL was transferred to
19.75 mL of Isoton II diluent (Coulter Electronics, Inc,
Hialeah, Fla), and the number of cells was determined with an
automatic cell counter (Coulter Electronics, Inc).
Spontaneous beating of cultured fetal cardiomyocytes
in the gelatin sponge. Both the cultured fetal cardiomyocytes
and their seeded patches beat spontaneously in the culture
dish. Forty-eight hours after plating, the synchronous beating
of fetal cell clusters was counted for 1 minute in 5 randomly
selected high-power microscopic fields (200×) (n = 10). The
pulse rate of the cell-seeded gelatin sponge patch was count-
ed for 1 minute under a low-power microscope (40×) 1 week
after seeding (n = 17).
Anesthesia and postoperative care of the recipient
rats.  Adult male Lewis rats, weighing 250 to 300 g, were
anesthetized with an intramuscular injection of ketamine
hydrochloride (22 mg/kg), followed by an intraperitoneal
injection of sodium pentobarbital (30 mg/kg). The rats were
endotracheally intubated and ventilated with a Harvard ven-
tilator (model 683; Harvard Bioscience, Inc, Holliston,
Mass). Positive-pressure ventilation was maintained at a
rate of 60 cycles/min with a tidal volume of 3 mL and room
air supplemented with oxygen (2 L/min). Penlong XL (peni-
cillin G benzathine, 150,000 U/mL, and penicillin G pro-
caine, 150,000 U/mL) was injected intramuscularly (0.4 mL
per rat). Buprenorphine hydrochloride (0.01 mg/kg body
weight) was given subcutaneously. Postoperatively, rats
were monitored until they fully recovered from the anesthe-
sia and were returned to their cages.
RVOT free wall resection and replacement with gelatin
sponge patches. The rat heart was exposed via a right lateral
thoracotomy under general anesthesia. A purse-string stitch
(5-6 mm in a diameter) was placed in the free wall of the
RVOT with 7-0 polypropylene sutures (Prolene; Ethicon, Inc,
Somerville, NJ). Both ends of the stitch were passed through
a 22-gauge plastic vascular cannula (Angiocath; Becton
Dickinson and Company, Franklin Lakes, NJ), which was
used as a tourniquet. The tourniquet was tightened and the
bulging part of the RVOT wall inside the purse-string stitch
was resected. The tourniquet was briefly released to deter-
mine whether massive bleeding occurred, which indicated
that a significant defect had been created in the RVOT. For
each type of cell culture, 2 pieces of gelatin sponge patch
were laid on top of each other and sewn along the margin of
the purse-string suture with over-and-over sutures with 7-0
polypropylene to cover the hole in the RVOT. After comple-
tion of suturing, the tourniquet was released and the purse-
string stitch was removed. 
Additional sutures were added, if needed, to achieve hemo-
stasis. The chest wound was closed in layers with running
sutures of 3-0 silk. Ten animals in each group had patches
inserted into the RVOT (fetal cardiomyocyte, n = 10; adult
cardiomyocyte, n = 10; and unseeded control, n = 10).
Histologic studies. At each scheduled period (4, 8, and 12
weeks), the animals were euthanized (n = 4 at 4 weeks and n =
3 at 8 and 12 weeks in each group) with an intrathoracic injec-
tion of 0.2 mL of pentobarbital sodium (Euthanyl; MTC
Pharmaceuticals, Cambridge, Ontario, Canada) after injection
of 300 units of heparin intramuscularly. Each heart was excised
through a repeated median sternotomy and fixed with 10%
phosphate-buffered formalin solution for 2 days. The right ven-
tricular free wall was cut in half along the center of the patch.
Overall appearance of the endocardial surface was examined.
The sections were either stained with hematoxylin and eosin as
described above or sent for immunohistochemical staining. 
Measurement of the area of the replacement in RVOT. The
patch in the RVOT was assessed macroscopically after heart
fixation. The endocardial surface of the right ventricular free
wall was exposed and photographed (n = 2 in each group).
The endocardial area of the patch was measured by comput-
ed planimetry (Jandal Scientific Sigma-Scan, Corte Madera,
Calif). 
Measurement of the thickness of the patch at RVOT. At 4 or
12 weeks after patch implantation, a microscopic image (10×
by Labophot microscope; Nikon Corporation, Tokyo, Japan) of
the section through the RVOT was taken by camera (FX-35;
Nikon Corporation). In each group, 4 rats were examined at 4
weeks and 3 at 12 weeks. A portion of the patch replacing the
defect in the RVOT was identified, and the thickness of the cen-
ter of the patch was measured at the same magnification (10×)
by Objective Micrometer (Nikon Corporation). At the same
time, 3 normal hearts were harvested and processed in the same
manner and the thickness of the RVOT was measured. 
Fig 4. Thickness of the RVOT. Data are shown as the mean ±
the standard deviation. The patches became significantly
thinner with time as the scaffold dissolved in all groups. No
difference in the thickness was found between the patch
groups at 4 or 12 weeks. Compared with normal hearts, the
fetal cardiomyocyte group was thicker (†P = .036) at 4
weeks, and the control group was thinner (‡P = .047) at 12
weeks. FCM, Fetal cardiomyocyte patch; ACM, adult car-
diomyocyte patch. *P = .003. **P = .001.
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Fig 5. Histologic studies of RVOT patch. A fetal cardiomyocyte patch 1 day after the implantation had tissue for-
mation (A, 100×; B, 400×). At 4 weeks an inflammatory reaction was seen in all groups as the gelatin scaffold dis-
solved. The adult group is shown in C (100×) and D (400×).  
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Cell identification. The cells expanded in vitro in the gelatin
sponge were labeled with the thymidine analog 5-bromo-2´-
deoxyuridine (BrdU; Sigma Chemical Co, St. Louis, Mo).
Two days before the RVOT patch implantation procedure, 25
µL of 0.4% BrdU solution was added to the culture dishes of
both fetal and adult cardiomyocytes and incubated for 48
hours. A monoclonal antibody against BrdU was used on the
heart specimen sections 12 weeks after implantation to local-
ize the labeled cells in the RVOT patches.6
Assessment of endothelialization with factor VIII staining.
A section of the patch in the RVOT was immunohistochemi-
cally stained with a monoclonal antibody for the factor
VIII–related antigen7 to assess the endothelialization on the
endocardial surface of the patch.
Data analysis. All data are expressed as the mean ± the stan-
dard deviation. By means of the SPSS software package for
Windows version 9.0 (SPSS Inc, Chicago Ill), the thickness of
the RVOT patches in 4 groups, including the control group 
(n = 3), was compared at 4 weeks and 12 weeks by 1-way
analysis of variance. The Scheffé test was used to specify dif-
ferences between groups. The thickness of the patches at 4
weeks was compared with that at 12 weeks by unpaired t test.
Results
Cell culture in the gelatin patch. The fetal car-
diomyocytes contracted regularly and spontaneously in
culture at a rate of 103.7 ± 20.9 beats/min (82-155
beats/min) (n = 10 dishes). The cell-seeded gelatin
sponges also contracted in the culture dishes. The pulse
rate of the patches was 76.7 ± 43.3 beats/min (29-165
beats/min) (n = 17 patches), which was lower (P = .08)
than that of the cultured cells.
Although the cells were seeded on the surface of
the gelatin patches, significant cellular infiltration
was noted inside the patches (Fig 1). There were no
differences in the patterns of cell distribution within
the patch for either fetal or adult cardiomyocytes.
The structure of the gelatin sponge was maintained
for the duration of the in vitro culture.
Fetal cardiomyocyte patches were cultured for 2 weeks
(Fig 2, A). In the first few days after the seeding, the cell
proliferation was not remarkable. However, cell numbers
increased significantly after 4 days, reaching the plateau
between 10 and 14 days. Adult heart cell patches were
cultured for 3 weeks (Fig 2, B). The number of cells
remained constant after 10 days. From the growth curve,
the doubling time was estimated at about 7 days.
Mortality. The mortality of the surgical procedure
was 16%. The operative deaths were mainly related to
technical problems. These included bleeding along the
suture line of the patch, left ventricular heart failure
resulting from hypoperfusion of the left anterior
descending coronary artery, or right ventricular failure
Fig 5. Cont’d.  The control group is shown in E (100×) and F (400×).
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resulting from acute RVOT stenosis during tightening
of the purse-string stitch on the RVOT. All of the rats
that survived the surgical procedure were alive until
scheduled euthanasia. When the rats were put to death
for histologic examination, no infection of the patch
occurred and no intrathoracic bleeding, which would
indicate rupture of the patch, was found in any of the
rats in this study.
RVOT patch. All animals had a full-thickness
replacement of RVOT defect with the gelatin patch (Fig
3). The area of the patch was 8.8 ± 3.0 mm2 (n = 6) at
4 weeks, which was 6.7% ± 2.9% of the endocardial
surface area of the free wall of the right ventricle. All
RVOT patches became thinner with time (Fig 4) (con-
trol group, P = .003; fetal group, P = .001; adult group,
P = .07) because of dissolution of the patch. No signif-
icant differences were found in the thickness of the
patch among the 3 groups, either 4 or 12 weeks after
the procedure. However, the patch in the control group
was thinner than the normal RVOT (P = .047) at 12
weeks, but the thickness of the fetal and adult cell-seed-
ed patches was similar to that of the normal RVOT.
The seeded cells formed a viable tissue within the
patch during the initial period after the replacement
(Fig 5, A and B). Four weeks after implantation an
active inflammatory response was found in all groups,
which slowly dissolved the gelatin scaffold. As a result,
the patches became thinner and some of the seeded
cells may have been eliminated (Fig 5, C and D). In the
control patches (Fig 5, E and F), the inflammatory
reaction was associated with the ingrowth of fibrous
tissue from the recipient heart.
At 12 weeks, the gelatin structure of the patches
had completely disappeared in all groups and the
inflammatory reaction had resolved (Fig 6, A, B, and
C). In the control group, the patch in the RVOT
became a thin fibrous tissue (Fig 6, A). In both heart
cell groups, the cells persisted in the patched area.
The cells were considered to be the seeded cultured
heart cells because they stained positively (brown)
for BrdU (Fig 7).
All groups showed a complete endothelialization on
the endocardial surface of the patch 4 weeks after the
operation (Fig 8, A, shows fetal cells). The pattern
resembled that of the normal endocardium (Fig 8, B).
The endothelialization process started as early as 3 days
Fig 6. Twelve weeks after the replacement (A, control group; B, adult group; C, fetal group; all magnified 100×).
The gelatin structure of the patches had completely disappeared and the inflammatory reaction had resolved.
Normal RVOT was shown for comparison (D, 100×).
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Fig 7. BrdU staining (B and D) with the corresponding hematoxylin and eosin staining (A and C) of the seeded patches at
12 weeks after the replacement (A and B, fetal group; C and D, adult group; 400×). Some of the cells in the patched area
stained positively (brown) for BrdU, indicating that they contained cultured cells seeded in the gelatin mesh.
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after the operation. The pattern and the timing of the
endothelialization were similar in all the groups. No
endocardial thrombus was found in any of the animals of
any group put to death 4 or 12 weeks after the operation.
Discussion
Tissue engineering. Tissue engineering is a novel
approach for the reconstruction of cardiac defects.8 The
group at the Boston Children’s Hospital used a
biodegradable polymer to create both a pulmonary
valve9 and a pulmonary artery10 in neonatal lambs.
These tissue-engineered grafts persisted after dissolu-
tion of the scaffold and grew with the animals. We hope
to exploit our ability to grow fetal and neonatal heart
cells to create a beating autologous conduit with an
autologous valve.
We3,4 recently reported the construction of a tissue-
engineered cardiac graft in vitro, with rat fetal or
neonatal cardiomyocytes. A biodegradable gelatin
sponge was used as a scaffold to establish cell
growth.11,12 The honeycomb structure of the gelatin
sponge allowed the growth of the seeded cells inside
the patch, which ensures the adequate perfusion of
nutrients and oxygen during culture. Also, the sponge
structure was soft enough to permit spontaneous con-
traction of the fetal or neonatal cardiomyocytes in
vitro. In our previous study, we3 inserted the beating
mesh containing either fetal or neonatal cardiomyo-
cytes into the subcutaneous tissue of syngeneic rats,
where the patch beat spontaneously for as long as 3
months after the implantation. The seeded cardiomyo-
cytes linked to each other by gap junctions and formed
Fig 8. Factor VIII staining (dark red) identified endothelial cells on the surface of the patch at 4 weeks after implan-
tation in all groups. The fetal cardiomyocyte group is illustrated in A (400×) and the normal endocardial surface is
shown in B (400×).
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a cardiac tissue, which beat synchronously. Blood ves-
sels were observed in the implanted patch, consisting
of an extensive capillary system as well as small arteri-
oles.3 The beating patch was also attached to the cry-
oinjured area of the left ventricle.3 The beating muscle
persisted after scaffold dissolution and induced an
intense angiogenesis.
Animal model. For this study, we used syngeneic
Lewis rats, which avoided rejection, but their small size
made our assessment difficult. The RVOT was chosen
because a possible application of the tissue-engineered
patch would be in patients who require a patch inser-
tion for an RVOT obstruction or stenosis. Additionally,
in previously published studies, various patch materials
were evaluated in the RVOT of larger animals.13-15
The major limitation of this small animal model was
our difficulty in assessing the hemodynamic effects of
the patch in the RVOT. We were unable to determine
whether the fetal cardiomyocytes continued to beat
synchronously after implantation. We found that the
cells formed a tissue, but we could not demonstrate
whether the tissue communicated with the host
myocardium. Soonpaa and colleagues16 showed that
transplanted fetal cardiomyocytes communicated with
the host myocardium by gap junctions. New advances
in echocardiography may permit an assessment of
regional wall motion of the cell-seeded patches and
other hemodynamic information in vivo.17
Cell-seeded patches. One major challenge to tissue
engineering is to induce and maintain cellular growth
into the interstices of the biodegradable scaffolding.
In our rat model, the thin patch permitted adequate
cell seeding in vitro and adequate perfusion of the graft
in vivo. In larger animals and human beings, a thicker
patch will be required and adequate seeding and perfu-
sion will be difficult.
To expand cell growth into the interstices of the
graft in vitro, we stacked thin cell-seeded grafts.4
Therefore, we were able to ensure an adequate cell
number in the middle of the graft at the time of
implantation. The Boston Children’s Hospital group
also used multiple layers of cell-seeded conduit
material to create a new pulmonary artery in lambs.10
They also used a pulse duplicator to circulate media
within their scaffold to create a cell-seeded pul-
monary valve.9 Therefore, techniques to increase cell
growth within biodegradable grafts have been suc-
cessful in larger animals.
In vivo studies demonstrated that cell-seeded grafts
induced an intense angiogenic response.3,4,9,10 In our
studies with fetal and neonatal cells in a beating patch
transplanted into the leg or onto the left ventricle, we
found an extensive capillary network within the beating
graft before and after the scaffold dissolved. We also
found arterioles and venules in and around the implant-
ed graft.3 Although many cells did not survive trans-
plantation, our studies and those from Boston9,10 sug-
gest that angiogenesis permitted survival of a sufficient
number of cells to maintain the patch or conduit after
the scaffold dissolved.
In the future, we hope to use neonatal heart cells to
produce a beating mesh in vitro. We could then
implant the autologous beating patch in the RVOT of
neonatal animals with the hope that we could create
pulsatile pulmonary perfusion. Autologous beating
conduits and autologous tissue-engineered valves pro-
vide the promise of a complete repair in neonates with
complex congenital heart defects.
Patch material. The best biodegradable material for
repair of cardiac defects has not been established.
Our gelatin sponge is advantageous for creating a
new cardiac chamber because it is soft and pliable.
However, the gelatin sponge induced an intense
inflammatory response. The gelatin sponge is derived
from porcine skin protein that may induce a
xenogenic reaction. We were surprised that endothe-
lialization developed rapidly on all grafts without
evidence of thrombus formation. A more biologically
compatible material that does not induce as intense
an inflammatory response would be preferable.
Improved biomaterials are essential to create a beat-
ing patch for human beings.
Future studies may identify a more ideal scaffold for
a tissue-engineered cardiac patch. It should be
biodegradable, allow for the growth of seeded cells, be
soft enough to allow spontaneous beating, and be able
to avoid an inflammatory reaction when implanted at a
site directly contacting host blood.
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Discussion
Dr Ray C. J. Chiu (Montreal, Quebec, Canada). If the patch
comprises only a few layers of cardiac myocytes, the nutrition
can come through by diffusion. However, if the muscle is to be
sufficiently thick to be useful for clinical purpose, the first prob-
lem is the blood supply. I do not think angiogenesis is the
answer, because it will take too long and the cell will be dead.
What is your solution? 
Dr Sakai. We agree that adequate perfusion of the cell-
seeded graft is essential. Diffusion may permit support of a
thin patch in experimental models, but angiogenesis, which
we have noted within 1 to 2 weeks after cell transplantation,
may also be required for cell survival in thicker, more clini-
cally useful grafts. This angiogenesis occurs before the
gelatin substrate is completely absorbed, which takes more
than 5 weeks. We have also found that non–cell-seeded grafts
form a fibrous patch after implantation in the right ventricu-
lar outflow tract of rats. It may be possible to seed cells into
these fibrous patches after implantation in the same way that
we have been able to transplant cells into a fibrous myocar-
dial scar.
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